Doxercalciferol is a synthetic form of vitamin D2 used to treat a condition called secondary hyperparathyroidism in people with chronic kidney disease (CKD). When your kidneys aren’t working well, they lose the ability to convert vitamin D into its active form, which causes your parathyroid glands to go into overdrive and produce too much parathyroid hormone (PTH). Doxercalciferol steps in as a replacement, helping restore the balance your kidneys can no longer maintain on their own.
How Doxercalciferol Works
Your body normally activates vitamin D through a two-step process involving the liver and kidneys. In chronic kidney disease, the kidney step fails. Doxercalciferol is designed to bypass that problem. After you take it, the drug is absorbed through the gut and then activated by a liver enzyme called CYP 27, which converts it into a form that mimics the active vitamin D your body needs. Because it relies on the liver rather than the kidneys for activation, it can still work even when kidney function is severely reduced.
Once activated, doxercalciferol helps your body absorb calcium from food and signals the parathyroid glands to slow down their production of PTH. Left unchecked, elevated PTH pulls calcium out of your bones, weakens them over time, and can contribute to dangerous calcium deposits in blood vessels and soft tissues.
Who Takes It and Why
Doxercalciferol is prescribed for people at different stages of chronic kidney disease. For those with stage 3 or 4 CKD (moderate to severe kidney function loss, but not yet on dialysis), the goal is to get ahead of rising PTH levels before bone and mineral problems become serious. For people with stage 5 CKD who are already on dialysis, it serves a similar purpose but often at different doses and with closer monitoring.
International kidney guidelines from KDIGO recommend that active vitamin D analogs like doxercalciferol not be used routinely in patients with CKD who aren’t on dialysis. Instead, they suggest reserving these medications for cases of severe and progressive hyperparathyroidism in more advanced kidney disease. For patients on dialysis who need PTH-lowering therapy, guidelines support using vitamin D analogs either alone or in combination with another class of drugs called calcimimetics.
How It Compares to Other Vitamin D Treatments
Doxercalciferol was developed alongside other active vitamin D analogs partly in hopes of reducing the risk of raising blood calcium levels too high, a side effect called hypercalcemia. Calcitriol, the oldest and most direct form of active vitamin D used in kidney disease, is effective at lowering PTH but carries this risk, especially at higher doses combined with calcium-based phosphate binders.
In practice, though, direct comparisons haven’t shown a clear safety advantage. A study published in Kidney International found no differences in episodes of hypercalcemia or elevated phosphorus levels between patients treated with calcitriol and those treated with doxercalciferol. Both drugs were equally effective at suppressing PTH and controlling bone turnover. The choice between them often comes down to a doctor’s clinical judgment, cost, and how a patient responds to treatment.
Available Forms
Doxercalciferol comes in two forms: oral capsules and an intravenous injection. The capsules are typically used by patients with earlier-stage CKD who are managing their condition at home. The injectable form is given during dialysis sessions by healthcare staff, which makes it practical for patients who are already receiving regular in-center treatments. The brand-name version is sold as Hectorol, though generic versions are also available.
Monitoring During Treatment
Taking doxercalciferol requires regular blood work. Your care team will track three key numbers: serum calcium, phosphorus, and intact PTH levels. How often those labs are drawn depends on your stage of kidney disease and whether you’ve recently started the medication or had a dose change.
For patients on dialysis, blood calcium, phosphorus, and PTH are typically checked weekly after starting the drug or adjusting the dose. Once things stabilize, calcium monitoring shifts to monthly for three months, then every three months. For patients with stage 3 or 4 CKD, the initial schedule is slightly less intense, with labs drawn at least every two weeks for the first three months, then monthly, then quarterly.
In clinical studies, doctors aimed to bring PTH levels into a range of 150 to 300 pg/mL for dialysis patients. For earlier-stage patients, the target was a reduction of at least 30% from baseline. The dose is adjusted up or down based on these lab results, so treatment is highly individualized.
Side Effects and Risks
The most important risk with doxercalciferol is hypercalcemia, which means calcium levels in your blood climb too high. Symptoms can include nausea, vomiting, constipation, excessive thirst, frequent urination, confusion, and fatigue. This is the primary reason for all the blood monitoring. If calcium levels rise above normal, the dose is reduced or the drug is temporarily stopped.
Elevated phosphorus levels (hyperphosphatemia) are another concern, since high phosphorus combined with high calcium increases the risk of mineral deposits forming in blood vessels and other tissues. People with existing hypercalcemia, high phosphorus levels, or signs of vitamin D toxicity should not take doxercalciferol.
Patients with liver problems need especially close monitoring. Because the liver is responsible for activating doxercalciferol, impaired liver function can make the drug’s effects less predictable, potentially requiring more frequent lab checks and dose adjustments.
Drug Interactions
Because doxercalciferol depends on a specific liver enzyme (CYP 27) for activation, medications that block or speed up that enzyme can change how well it works. Drugs like ketoconazole (an antifungal) and erythromycin (an antibiotic) can slow down the enzyme and reduce the amount of active drug your body produces. On the other hand, enzyme inducers like phenobarbital can push the enzyme in the opposite direction. Starting or stopping any of these medications may mean your doxercalciferol dose needs adjustment.
There’s also a specific interaction with magnesium-containing antacids. Dialysis patients who take these alongside doxercalciferol risk developing dangerously high magnesium levels, so the two should not be used together.